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Abstract. Alteration of mitochondria-associated membranes (MAMs) has been proposed to contribute to the pathogenesis
of Alzheimer’s disease (AD). We studied herein the subcellular distribution, the processing, and the protein interactome of
the amyloid- protein precursor (APP) and its proteolytic products in MAMs. We reveal that APP and its catabolites are
present in MAMs in cellular models overexpressing wild type APP or APP harboring the double Swedish or London
familial AD mutations, and in brains of transgenic mice model of AD. Furthermore, we evidenced that both - and -
secretases are present and harbor APP processing activities in MAMs. Interestingly, cells overexpressing APPswe show
increased ER-mitochondria contact sites. We also document increased neutral lipid accumulation linked to A production
and reversed by inhibiting - or -secretases. Using a proteomic approach, we show that APP and its catabolites interact
with key proteins of MAMs controlling mitochondria and ER functions. These data highlight the role of APP processing
and proteomic interactome in MAMs deregulation taking place in AD.
Keywords: Alzheimer disease, amyloid- protein precursor, lipids, mitochondria associated membranes, proteomic
INTRODUCTION
Alzheimer’s disease (AD) is a devastating neu-
rodegenerative pathology characterized by the
∗Correspondence to: Mounia Chami, Universite´ Coˆte d’Azur,
INSERM, CNRS, IPMC, France, Laboratory of excellence Dis-
tALZ, 660 route des Lucioles, 06560, Sophia-Antipolis, Valbonne,
France. Tel.: +33 493953457; Fax: +33493953408; E-mail:
mchami@ipmc.cnrs.fr.
progressive decline of cognitive functions. The accu-
mulation of intracellular aggregates of tau protein
in the neurofibrillary tangles and of extracellular
aggregates of a set of polypeptides called amyloid-
 peptides (A) in the senile plaques [1] are the
major histological hallmarks of AD. A peptides
are generated from a large transmembrane protein,
the amyloid- protein precursor (APP) through its
sequential cleavage by the -secretase generating the
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C-terminal fragment (CTF) of 99 amino acids (C99),
and by the -secretase releasing A peptide, and the
APP intracellular domain (AICD) [2]. Cleavage of
APP by -secretase precludes the formation of A
peptides and leads to the generation of another CTF
of 83 amino acids (C83) [3, 4].
A peptides are generated extracellularly, but also
within intracellular organelles such as the endo-
plasmic reticulum (ER) and mitochondria. APP
is folded and modified in the ER and transported
through the Golgi complex to the plasma membrane.
It was proposed that A is generated in the ER lumen
as a result of deficits in axonal transport [5]. A
oligomers (considered to be the most toxic forms of
A) accumulate in the ER in hippocampal neurons
and thereby, likely lead to cell death in transgenic
mice expressing APP mutant [6]. Association of
APP with mitochondria was also reported by sev-
eral groups [7–9]. A was shown to accumulate into
mitochondria prior to extracellular plaques and in
a time-dependent manner, leading to mitochondrial
damage [10–12]. In addition, different components
of the -secretase complex have been located in dif-
ferent subcellular compartments, including the ER
and mitochondria [9, 13–16].
Physical association between the ER and mito-
chondria, also known as mitochondria-associated
membranes (MAMs), play important roles in
various cellular housekeeping functions such as
phospholipids-, glucose-, cholesterol-, and fatty-
acid- metabolism, as well as calcium signaling [17,
18]. The hypothesis stating that AD could be a disor-
der linked to MAMs alterations started to emerge only
in the last 6 years [19–21]. In this study, we show that
APP and its catabolites accumulate in MAMs and
increase ER-mitochondria contact sites. We also evi-
dence that both -secretase and -secretase complex
are present and may harbor enzymatic activities in
MAMs. Of most importance, we document increased
neutral lipid accumulation in cellular models of AD,
which was reversed by inhibiting - or -secretases.
A proteomic approach revealed the protein interac-
tome of APP and its catabolites with key proteins of
MAMs controlling mitochondria and ER functions.
MATERIAL AND METHODS
Cells
Human SH-SY5Y neuroblastoma cells (CRL-
2266, ATCC) stably expressing pcDNA3.1 (control),
wild type human APP (APPwt), or human APP
harboring the double Swedish mutations (APPswe:
APPKM670/671NL) constructs were generated as
already described [22]. Polyclonal stable lines were
maintained in DMEM containing 10% FBS in the
presence of 400g geneticin (Gibco).
Mock-transfected or APP695LDN-expressing
CHO cells were obtained by stable transfection of
pcDNA4 empty vector (Control), wild type hAPP695
cDNA or harboring the London mutation (APPLDN:
APPV642I) and subcloned in pcDNA4 vector. Single
clones were maintained in DMEM containing 10%
FBS, sodium hypoxanthine-thymidine supplement,
and 300M proline as already described [23].
Cells were treated overnight (20 h) with - or -
secretase inhibitors. -secretase inhibitor ELND006
was used at 5M final concentration and vehi-
cle (methylcellulose/polysorbate 80; Sigma-Aldrich)
was used as control [24, 25].-secretase inhibitor (Eli
Lilly’s inhibitor LY288672 [26], synthesized by Elan
Pharmaceutical) was used at 30M final concentra-
tion prepared in DMSO. Vehicle was used as control
since no difference was observed as compared to cells
treated with DMSO.
Mice
We used brains isolated from double-
transgenic APP23xPS45 mice (B6-Tg hAPP751
K670N/M671 L×PS1 G384A mThy1). These mice
were obtained through Material Transfer Manage-
ment from Novartis. To generate APP23xPS45 mice,
we crossed APP23 transgenic line overexpressing
hAPP with the Swedish double mutation at posi-
tions 670/671 [hAPP751: K670N/M671L], with
PS45 transgenic line overexpressing human PS1
carrying G384A mutation [hPS1: G384A] [27].
Both lines are driven by a Thy-1 promoter and were
developed in C57BL/6 genetic background. Control
wild type (WT) mice were from the same genetic
background.
Ethics statements
In vivo experiments were performed in accordance
with relevant guidelines and regulations established
by the European community council (Directive of
November 24, 1986), and approved by Nice Univer-
sity Animal care and use Committee, and the National
Council on animal care of the Ministry of Health
(Project n◦: NCE/2013-152). Mice were housed in
SPF animal facility.
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Cellular fractionation
Cell fractionation was performed using SH-SY5Y
and CHO cell lines, and brains dissected from WT,
APP23, PS45, and APP23xPS45 mice using an opti-
mized protocol to isolate subcellular fractions from
tissues and cells [28]. Cells (≈109) were harvested,
washed by centrifugation at 500 × g for 5 min with
PBS. Cells or brains (n = 5 for each mice group)
were resuspended in homogenization buffer (225 mM
mannitol, 75 mM sucrose, 30 mM Tris-HCl pH 7.4,
0.1 mM EGTA) and gently disrupted by Dounce
homogenization at 4◦C. The homogenate was cen-
trifuged twice at 600 × g for 5 min to remove nuclei
and unbroken cells, and then the supernatant was
centrifuged at 10 300 × g for 10 min to pellet crude
mitochondria (Mc). The resultant supernatant was
centrifuged at 20 000 × g for 30 min at 4◦C. The
pellet consists of lysosomal and plasma membrane
fractions. Further centrifugation of the obtained
supernatant at 100 000 × g for 90 min (70-Ti rotor;
Beckman, France) at 4◦C results in the isolation
of ER (pellet) and cytosolic fraction (supernatant).
The crude mitochondrial (Mc) fraction, resuspended
in MAM isolation buffer (250 mM mannitol, 5 mM
HEPES pH 7.4 and 0.5 mM EGTA), was subjected
to Percoll gradient centrifugation (Percoll medium:
225 mM mannitol, 25 mM HEPES pH 7.4, 1 mM
EGTA, and 30% vol/vol Percoll) in a 10-ml poly-
carbonate ultracentrifuge tube. After centrifugation
at 95,000 × g for 30 min (SW40 rotor; Beckman,
France), a dense band containing purified mitochon-
dria (Mp) was recovered approximately 3/4 down of
the tube, resuspended in MAM isolation buffer and
washed by centrifugation at 6300 × g for 10 min to
remove the Percoll and finally resuspended in small
volume of MAM isolation buffer. The MAMs, con-
taining the structural contacts between mitochondria
and ER, collected from the Percoll gradient as a dif-
fuse white band located above the mitochondria, were
diluted in MAM isolation buffer and centrifuged at
6300 × g for 10 min; then the supernatant was further
centrifuged at 100 000 × g for 90 min (70-Ti rotor,
Beckman) to pellet the MAMs fraction.
SDS-PAGE analysis
To detect A peptide, protein extracts (40g) were
incubated with 70% formic acid (Sigma) and Speed
Vac evaporated for 40 min. The pellets were dis-
solved in 1 M Tris pH 10.8, 25 mM Betaine and
diluted in 2x Tris-Tricine loading buffer (125 mM
Tris-HCl pH 8.45, 2% SDS, 20% Glycerol, 0.001%
Bromophenol blue, and 5% -mercaptoethanol).
Proteins were resolved by 16.5% Tris-Tricine SDS-
PAGE, transferred onto PVDF membranes, and
incubated overnight with specific antibodies as spec-
ified in legends. All the other proteins were resolved
by Tris-Glycine SDS-PAGE following standard pro-
cedures.
Antibodies
A, C99, and full length APP were detected using
6E10 antibody (Covance) recognizing 1-16 residues
of A. APP C-terminal fragments (APP CTF: C99
and C83), were detected using APP C-terminal anti-
body (Sigma Aldrich) recognizing 676–695 residues
of APP. Other antibodies directed toward the fol-
lowing proteins were as follow: Cytochrome C
oxidase subunit II (Cox), and RyR (Thermo scien-
tific); VDAC-1 (Calbiochem); HSP60, Calreticulin,
and GRP75 (Santa Cruz); Chapronin 10 (Stressgen,
Biotech); Nicastrin, Tom20, -Tubulin, and -Actin
(Sigma Aldrich), SERCA2b (clone IID8), and Aph1
(Thermo Scientific Pierce Products); BACE-1 and
Cytp450 (Abcam); PS1-Nter is a generous gift from
Gopal Thinakaran.
Detection of Aβ by ELISA
The concentrations of A40 and A42 were mea-
sured in subcellular fractions by using the respective
ELISA kits (Invitrogen) following the manufacturer’s
instructions. Briefly, 40g of each fraction was
treated with 5 M guanidine, 50 mM HCl solution
for 3-4 h at room temperature and stored at –20◦C
overnight. Supernatant obtained after centrifugation
at 16,000 rpm for 20 min at 4◦C, were diluted at >1/10
in D-PBS-BSA 5% and used for ELISA.
In vitro α-secretase assay
-secretase activity was monitored as already
described [29]. Briefly, 20g of each subcellular
fraction were incubated in 90l final volume of
Tris buffer (10 mM, pH 7.5) containing -secretase
substrate (JMV2770, 100M) in the absence or pres-
ence of the metal chelatoro-phenanthroline (100M)
reported to block metalloproteases.-secretase activ-
ity corresponds to the -secretase inhibitor-sensitive
fluorescence recorded at 320 and 420 nm as excitation
and emission wavelengths, respectively.
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In vitro β-secretase assay
-secretase activity was monitored as already
described [22]. Briefly, 20g of each subcellu-
lar fraction were incubated in a final volume
of acetate buffer (25 mM, pH4.5, 100l) con-
taining BACE-1 substrate [(7-methoxycoumarin-
4-yl)-acetyl-SEVNLDAEFRK (2,4-dinitrophenyl)-
RRNH2; 10m; R&D Systems] in the absence or
presence of -secretase inhibitor I (50m; Promo-
Cell). BACE-1 activity corresponds to the-secretase
inhibitor I-sensitive fluorescence recorded at 320
and 420 nm as excitation and emission wavelengths,
respectively.
In vitro γ-secretase assay
In vitro -secretase assay was assessed as already
described [30]. Twenty g of each subcellular
fraction were resuspended in solubilization buffer
(150 mM sodium citrate pH6.4 containing 3-[(3-
cholamydopropyl) dimethylammonio]-2-hydroxy-1-
propanesulfonate 1% (v/v)) supplemented with
protease inhibitor mixture. All steps were performed
at 4◦C. Solubilized membranes were diluted once
with sodium citrate buffer (150 mM pH 6.4), and
with reaction buffer (150 mM sodium citrate pH
6.4, 20 mM dithiothreitol, 0.2 mg/ml BSA, 1 mg/ml
egg phosphatidyl choline and 50g/mL recombinant
C100-FLAG). The resulting reaction mix were then
either incubated over constant agitation for 16 h at
37◦C or stored at 4◦C (negative controls). Samples
were then supplemented with 2x Tris-Tricine load-
ing buffer, boiled for 5 min and subjected to 16.5%
Tris-Tricine SDS-PAGE.
Immunoﬂuorescence analysis
Cells grown on 25 mm round coverslips were fixed
in PFA 4% solution for 10 min at room temperature.
Cells were permeabilized with triton 0.5%, and non-
specific binding sites were blocked for 1 h with BSA
(5%). Cells were then incubated at 4◦C overnight
with primary antibodies diluted in BSA (5%). After
3 washes, coverslips were incubated with secondary
antibodies [fluorescent Alexa Fluor antibodies, Alexa
488- and Alexa 594- or Alexa 633-conjugated (Invit-
rogen; 1:1000)] at room temperature during 1 h.
Immunofluorescence images were acquired on Leica
SP5 confocal microscope using excitation filters
488, 594, and 633 nm. Images were analyzed using
ImageJ.
High resolution imaging
To visualize mitochondria and ER organelle
colocalization, we used GFP construct specifically
targeted to the ER. Mitochondria were labeled by
using 10 nM Mitotraker® Deep Red dye. Z-series
images acquired on Leica SP5 microscope were
deconvolved. ER and mitochondria colocalization
was calculated as the number of voxels (volume
pixels) occupied by both signals (i.e., erGFP and
Mitotraker Deep Red) over all voxels occupied by
the mitochondria (i.e. Mitotraker® Deep Red signal)
in thresholded images [31]. The spectral proprieties
of these two fluorochromes allow specific identifica-
tion of the two compartments and quantification of
contact sites.
Electron microscopy
Cells were fixed in situ with 2.5% glutaralde-
hyde in 0.1 M phosphate buffer at room temperature
(RT) for 20 min. Samples were rinsed and then
post-fixed with 1% osmium tetroxide and 1% potas-
sium ferrocyanide in 0.1 M cacodylate buffer for
1 h at RT to enhance the staining of cytoplasmic
membranes. Cells were rinsed with distilled water,
embedded in epoxy resin, sectioned, and examined
with a Philips CM12 transmission electron micro-
scope equipped with an Olympus SIS CCD camera.
Images were acquired randomly by a blinded investi-
gator. We counted the total number of mitochondria
(n > 150) in contact or not with ER in more than 10
different micrographs obtained from two different
experiments. Data are presented as a percentage of
mitochondria in contact with ER.
Neutral lipid staining
Cells grown on 25 mm round coverslips were fixed
in PFA 4% solution for 20 min at room temper-
ature. Fixed cells were gently rinsed with PBS 3
times to remove residual formaldehyde. Cells were
stained with 1X LipidTOX™ prepared in PBS for
30 min at room temperature. Coverslips were then
processed for image acquisition on Leica SP5 con-
focal microscope using excitation filters 488. Images
were thresholded, converted to mask and analyzed
using Particle analysis ImageJ plugin.
Oligomeric Aβ preparation
Human synthetic A1–42 (Bachem AG, Switzer-
land) was suspended in hexafluoroisopropanol,
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HFIP; Sigma–Aldrich) to 1 mM. Peptide samples
were vortexed to obtain a homogenous solution,
aliquoted into microfuge tubes, and lyophilized
overnight under the hood. The A1–42 peptide films
were stored desiccated at –20◦C until further pro-
cessed. To form A oligomers, peptide films were
resuspended to 5 mM in DMSO, diluted in ice cold
PBS. Aggregation was allowed to proceed for 24 h at
4 ◦C before the peptide solution was centrifuged at
14000 × g for 10 min at 4◦C. Supernatant containing
oligomeric A was then used at ≈5M.
Immunoprecipitation and in-gel digestion
After preclearing with protein A-agarose (Sigma-
Aldrich) (1 h, 4◦C), MAM fractions (40g) isolated
from control CHO cells and overexpressing APPLDN
were immunoprecipitated using 6E10 antibody
(5g). Immunoprecipitates were recovered by
overnight incubation at 4◦C, and then incubated with
protein A-agarose for 3 h at 4◦C. Beads were washed
three times with CHRIS buffer (50 mM Tris pH
8, 10% glycerol, 200 mM NaCl, 0.5% Nonidet p-
40, and 0.1 mM EDTA) supplemented with protease
inhibitors (Complete, Roche diagnostics) and once
with PBS. Beads were then resupended in Laemli 2x
buffer, heated at 95◦C, and then run on Tris-Glycine
PAGE. Gels were stained using Imperial Protein Stain
(Thermo scientific), a ready-to-use colorimetric stain
formulated with Coomassie dye.
Gel pieces containing proteins were excised and
distained by adding 100L of H2O/ACN solvent
(1/1). After 10 min incubation with vortexing the liq-
uid was discarded. This procedure was repeated 2
times. Gel piece were then rinsed (15 min) with ace-
tonitrile and dried under vacuum. Gel pieces were
reswelled in 50L of 20 mM dithiothreitol (DTT) in
NH4HCO3 100 mM, incubated for 30 min at 56◦C,
and next cooled down to RT. The DTT solution was
replaced with 50L of 55 mM of iodoacetamide
in 100 mM of NH4HCO3. After 15 min incubation
in the dark at room temperature, the solution was
discarded and gel pieces were washed by adding suc-
cessively i) 100L of H2O/ACN (1/1), repeated 2
times and ii) 100L of acetonitrile. Next gel pieces
were reswelled in 50L of 50 mM NH4HCO3 buffer
containing 10 ng/L of trypsin (modified porcine
trypsin sequence grade, Promega) incubated for 1 h at
4◦C. Then the solution was removed and replaced by
50L of 50 mM NH4HCO3 buffer (without trypsin),
and incubated 18 h at 37◦C. After trypsin digestion
the solution was transferred into an Eppendorf tube
and tryptic peptides were extracted with i) 50L of
1% AF (acid formic) in water (10 min at RT) and ii)
50L acetonitrile (10 min at RT). Peptides extracts
were pooled, concentrated under vacuum and solubi-
lized in 15L of 0.1% TFA (trifluoroacetic acid) in
water.
NanoHPLC-MALDI-TOF/TOF analysis
Peptide separation was carried out using a
nanoHPLC offline (ultimate 3000, Thermo Fisher
Scientific) coupled with a MALDI-TOF/TOF mass
spectrometer (4800 plus, Applied Biosystems). Pep-
tides solution was concentrated on a -Precolumn
Cartridge Acclaim PepMap 100 C18 (i.d. 5 mm,
5m, 100A˚, Thermo Fisher Scientific) at a flow
rate of 20L/min and using solvent containing
H2O/ACN/TFA 98%/2%/0.04%. Next peptides sep-
aration was performed on a 75m i.d. × 150 mm
(3m, 100 A˚) Acclaim PepMap 100 C18 col-
umn (Thermo Fisher Scientific) at a flow rate of
200 nL/min and with detection at 214 nm. Sol-
vent systems were: (A) 100% water, 0.05% TFA,
(B) 100% acetonitrile, 0.04% TFA. The follow-
ing gradient was used t = 0 min 100% A; t = 3 min
100% A; t = 63 min, 80% B; t = 64 min, 100%
B; t = 69 min 100% B (temperature was regulated
at 30◦C).
For offline nanoHPLC-MALDI-TOF/TOF-MS
and MS/MS analyses, fractions were collected on an
Opti-TOF LC/MALDI target (123 × 81 mm, Applied
Biosystems) and fractionation was done using the
Probot fractionation robot (DIONEX, LC Packings).
Matrix solution (-cyano-4-hydroxycinnamic acid,
2.5 mg/mL in 50% water, 50% acetonitrile, 0.1% TFA
solution) and nanoHPLC fractions were mixed (in
rate 4:1, matrix:fractions) and collected every 20 s
(208 fractions were collected per run).
MS spectra were recorded automatically in a mass
range of 700–4000 Da resulting from 200 laser shots
of constant intensity. Data were collected using 4000
series Explorer (Applied Biosystems) allowing for
an automatic selection of peptide masses for sub-
sequent MS/MS experiments. Each MS/MS spectra
acquired using 1000 laser shots were further pro-
cessed using 4000 series Explorer. Finally all raw data
were transferred into ProteinPilot software (Applied
Biosystems, MDS Analytical Technologies) and pro-
teins identification was processed using ParagonTM
Algorithm. Our analyses took in consideration only
peptides with confidence index 95%. This experiment
was done twice.
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Statistical analyses
Results are reported from at least three different
experiments or as indicated. Statistical analyses were
done using Student’s t-test, or ANOVA one-way and
Tukey post-test or Newman-Keuls Multicomparison
post-test. p value <0.05 was considered significant.
RESULTS
AβPP and its proteolytic products are present in
MAMs fraction of in vitro and in vivo study
models of AD
We first aimed at establishing by subcellular
fractionation, the distribution of APP and its
proteolytic catabolites in human SH-SY5Y neurob-
lastoma cells stably expressing pcDNA3.1 (control)
or human APP harboring the double Swedish muta-
tions (APPswe: APPKM670/671NL) constructs. We
already reported that SH-SY5Y cells expressing
APPswe harbor increased APP processing yielding
the production of APP CTFs fragments (C99 and
C83) and of A peptides [22].
We investigated the presence of APP and its
proteolytic catabolites in MAMs. Although several
techniques are available to isolate mitochondria,
only few are specifically tuned to the isolation of
MAMs, containing unique regions of ER mem-
branes attached to the outer mitochondrial membrane
and mitochondria without contamination from other
organelles (i.e., pure mitochondria). We used an
optimized protocol to isolate these fractions from
tissues and cells [28]. Subcellular fractionation pro-
cedure was validated by confirming the expression
of different proteins in cellular compartments where
they were known to be enriched, namely in the
ER (SERCA2b, calreticulin (CRT)), in mitochondria
(cytochrome oxidase subunit II (Cox), and voltage
dependent anion channel 1 (VDAC1)), and in MAMs
(Glucose regulated protein 75 (GRP75)) (Fig. 1A,
B). Fraction enrichment was further demonstrated
by the loss of actin signal in pure mitochondria
(Mp), ER, and MAMS fractions (Fig. 1A, B). We
observed APP and A expressions in the whole
homogenate (homog), in crude mitochondria (Mc),
in pure mitochondria (Mp), and in ER fractions
(Fig. 1B). Interestingly, we noticed the presence of
full-length APP and of A in MAMs fraction of
APPswe expressing cells (Fig. 1B). Full-length APP
was also observed in MAMs fraction of control cells,
thus indicating that both endogenous and overex-
pressed APP are present in MAMs. However, only
a slight A signal was noticed in control cells. This
may be related to low expression level of APP in
control cells.
We then investigated APP subcellular localiza-
tion in a second cellular model expressing the London
APP mutation (APPLDN: APPV642I). In fact, while
the Swedish mutation increases the rate of-cleavage
and is proposed to alter the trafficking of APP [32],
the “London” mutation increases the relative amount
of the more toxic A42 produced by -cleavage,
but is not proposed to alter trafficking [33]; Fur-
thermore, It was already reported that CHO cells
expressing APPLDN yield high levels of intracellu-
lar and secreted A oligomers [23, 34], and several
lines of evidence concord to demonstrate that at least
part of the AD-related neurodegenerative process
could be due to A oligomers [34]. Thus, we car-
ried out similar analyses on control and APPLDN
cells (Supplementary Figure 1A). We revealed the
presence of full length APP, and its C-terminal
fragments (C99 and C83), and of A in the whole
homogenate, and in Mc, ER, and MAMs fractions
of CHO cells expressing APPLDN (Supplementary
Figure 1A). Of most interest, we also revealed sup-
plementary bands (Supplementary Figure 1A, see
(*) symbol) likely corresponding to dimeric and low
molecular oligomeric forms of A in the Mc and
MAMs fractions of CHO cells expressing APPLDN
(Supplementary Figure 1A). In this model, we also
observed the presence of full-length APP in MAMs
fraction of control cells. These first set of data show
that APP, CTFs, and A are present in MAMs in
two in vitro models of AD.
We then examined whether APP and A could
also be present in MAMs, in vivo. We measured
expressions of APP and its catabolites C99, C83,
and A in subcellular fractions prepared from brains
isolated from WT and transgenic mice expressing
human APP harboring the double Swedish muta-
tions (APPswe: APP23), human presenilin 1 (PS1)
(component of the -secretase complex) mutation
(PS45: G384A), or both (APP23xPS45). Cytochrome
p450 (Cytp450, an ER resident protein (Fig. 1A)
was indeed enriched in the ER fraction (Fig. 1C).
Chapronin 10 (Cpn10), a mitochondrial protein
(Fig. 1A) was detected in the homogenate and Mc,
and largely enriched in Mp fraction (Fig. 1C). Both
APP23 and APP23xPS45 showed APP, its C-terminal
fragments (C99 and C83), and A expression in
MAMs fraction (Fig. 1C). Interestingly, we also
noticed the presence of C83 but to a lesser extent than
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Fig. 1. APP and its catabolites are present in MAMs fraction. A) Scheme representing ER-mitochondria contact sites and the molecular
markers of ER and mitochondria used. MRC, mitochondrial respiratory chain. B, C) Representative SDS-PAGE of subcellular fractions
isolated from: (B) SH-SY5Y neuroblastoma cells expressing pcDNA3.1 empty vector (Control) or hAPP695 harboring double Swedish
mutations (APPKM670/671NL: APPswe), and (C) brains of WT mice, PS45, APP23, and APP23xPS45 transgenic mice. We load 40g (B) or
20g (C) of total homogenate (homog), Crude mitochondria (Mc), pure mitochondria (Mp), the endoplasmic reticulum (ER), and MAMs
fractions. APP, C99, and A were detected by 6E10 antibody. APP C-terminal fragments (C99 and C83) were detected by APP C-ter
antibody. SERCA2b, calreticulin (CRT), and Cytochrome p450 (Cytp450) were used as loading controls for ER fraction. Cox, VDAC1, and
Chapronin 10 (Cpn10) were used as loading controls for Mc and Mp fractions. GRP75 was used as loading controls for MAMs fraction. Actin
and Tubulin were used as loading controls. Data are representative of 3 independent experiments for (B), and were obtained from 5 animals
per group of mice and repeated twice for (C). D) ELISA of A40 and A42 done on subcellular fractions isolated from APP23 transgenic
mice. Graph represents Mean ± S.E.M from three experiments and expressed in pg per g of proteins. *p value <0.05, **p value <0.01, ***p
value <0.001 calculated using ANOVA one way and Newman-Keuls Multicomparison post-test.
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C99 in WT and PS45 mice (Fig. 1C). The increased
C99 fragment in APP23 and APP23xPS45 is likely
linked to the overexpression of the Swedish muta-
tion known to increase the rate of -cleavage [32].
Finally specific ELISA approaches allowed unrav-
eling both A1-40 and A1-42 peptides in MAMs
fraction of APP23 (Fig. 1D). We also unraveled a
slightly elevated A40/A42 ratio in Mc, ER, and
MAMs as compared to homogenate and Mp fractions.
Overall, this set of data indicates that APP and its
catabolites are present in MAMs in vivo (Fig. 1C,
D) in agreement with the in vitro data (Fig. 1B and
Supplementary Figure 1).
Immunolocalization of AβPP and its catabolites
in the ER, mitochondria, and MAMs
We then analyzed subcellular localization of APP
and its catabolites by immunofluorescence in SH-
SY5Y cells expressing APPswe. We investigated the
extent of APP, and its catabolites co-localization
with the ER and mitochondria by using APP C-ter
antibody (recognizing full length APP, C-terminal
fragments (C83 and C99), and APP intracellular
domain (AICD)), or 6E10 antibody (recognizing full
length APP, C99, and A peptides) concomitantly
with specific antibodies recognizing proteins local-
ized in the ER (the ryanodine receptor (RyR) and
Cytp450), or in the mitochondria (Tom20 and Cox).
Representative images show the co-localization (yel-
low signal) of APP and its catabolites with both
the ER (Fig. 2A, C), and mitochondria (Fig. 2B,
D) markers. Similar results were obtained in CHO
cells expressing APPLDN using APP C-ter antibody
(Supplementary Figure 1B, C).
We then examined APP and its catabolites
colocalization within ER-mitochondria contact sites.
SH-SY5Y cells expressing APPswe were immuno-
labeled concomitantly with APP C-ter, Tom20, and
the ER-resident protein calreticulin (CRT) antibodies
(Fig. 2E). Merge, high magnificence images (Fig. 2E,
merge and inset), and super imposable line scan
traces (Fig. 2F) (corresponding to the red, green,
and blue fluorescence signals along the red line in
the inset) demonstrate co-localization of APP and
CTFs with both ER and mitochondria. These data
are in agreement with our data obtained by subcellu-
lar fractionation and further support the presence of
APP and its metabolites in MAMs in cellular mod-
els overexpressing both the Swedish and the London
mutations.
Full length APP as revealed by using specific
antibody recognizing APP N-terminal epitope (APP
N-ter) shows also slight co-localization with the ER
(Supplementary Figure 3A) and mitochondria (Sup-
plementary Figure 3B).
Using immunofluorescence and imaging, we also
examined the subcellular distribution of wild type
APP in both SH-SY5Y and CHO cells. We show
the immunolocalization of WT APP and its metabo-
lites in the ER (colocalization with SERCA2b)
(Supplementary Figures 3A and 4A), mitochondria
(colocalization with mitochondrial HSP60) (Supple-
mentary Figures 3B and 4B), and MAMs (Supple-
mentary Figures 3C, D and 4C, D) in both SH-SY5Y
(Supplementary Figure 3) and CHO (Supplementary
Figure 4) cells overexpressing wild type APP. The
results reveal that like the Swedish and London
mutated APP, wild type APP harbor partial colo-
calization with the ER, mitochondria, and MAMs.
These data strengthen our conclusion regarding the
subcellular localization and proteolytic processing of
APP in MAMs.
β- and γ-secretases are present and show in vitro
activities in MAMs fraction
We next revealed by subcellular fractionation
of APP23 transgenic mice brains the presence of
-secretase (BACE-1) and of components of the
-secretase complex (PS1, Aph1, and nicastrin) in
MAMs (Fig. 3A). In vitro -secretase activity assay
allowed us to reveal the hydrolysis of recombinant
C100 fragment at 37◦C and not at 4◦C (used as
negative control) that yield A production in the
homogenate, Mc, Mp, ER, and MAMs fractions iso-
lated from brains of APP23 mice (Fig. 3B). We did
not notice a difference in-secretase activity between
WT and APP23 mice (Supplementary Figure 5A).
Similarly, -secretase activity was also observed in
MAMs fraction isolated from CHO cells expressing
APPLDN (Supplementary Figure 5B). In agreement
with BACE-1 expression in APP23 MAMs (Fig. 3A),
we detect -secretase activity in MAMs fraction in
both WT and APP23 mice fractions (Fig. 3C), and
in control CHO cells and expressing APPLDN (Sup-
plementary Figure 5C). Related to the presence of
C83 (the -secretase-derived CTF) in vivo (Fig. 1C),
we also measured -secretase activity in subcellu-
lar fractions isolated form APP23 transgenic mice.
We indeed could observe in vitro -secretase activity
in the homogenate, Mc, ER, and MAMs. However,
the in vitro -secretase activity was lower in MAMs
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Fig. 2. APP and its catabolites colocalize with ER and mitochondria. A, B) Immunostaining of SH-SY5Y APPswe cells with APP C-ter
antibody recognizing total APP and CTF (C99 and C83). RyR was used to stain the ER (A). Tom20 was used to stain mitochondria (B).
C, D) Immunostaining of SH-SY5Y APPswe cells with 6E10 antibody recognizing total APP, C99, and A peptides. Cytp450 was used
to stain the ER (C). Cox was used to stain mitochondria (D). A-D) Merge images show green and red signals and were used to show the
colocalization of APP and its catabolites with the ER or mitochondria (yellow signal). Scale bars represent 10m. E) Immunostaining of
SH-SY5Y APPswe cells with APP C-ter, Tom20, and calreticulin (CRT) antibodies. Merge images show overlay of green, red and blue
signals, where colocalization is depicted in white (see merge image and magnified overlay). Scale bar represents 10m. F) RGB (Red, Green,
Blue) profile plots of a representative line scan (red line in inset) shows the maximum intensity of Red, Green, and Blue plots observed at
the same distance, and demonstrating the colocalization of Red (Tom20), Green (C-ter), and Blue (CRT) signals.
as compared to the other fractions (Supplementary
Figure 5D). All over, and according to already pub-
lished data [9, 13, 16, 20], we revealed the presence
and activity of -secretase in MAMs fraction. We
also provide for the first time evidences showing that
BACE-1 is present in MAMs fraction and that BACE-
1 and -secretase may harbor enzymatic activities in
this domain.
Increased ER and mitochondria contacts in
SH-SY5Y neuroblastoma APPswe cell model
Increased ER-mitochondria colocalization has
been reported in human-derived fibroblasts isolated
from familial and sporadic AD patients and in mouse
embryonic fibroblasts isolated from either PS1 or PS1
and PS2 knockout mice [21]. This was also observed
in cells overexpressing familial AD PS2 mutant [35].
We examined herein ER-mitochondria contact sites
in live cells overexpressing APPswe (Fig. 4A). For live
cells imaging, the ER was visualized by transfecting
GFP construct targeted to the ER (ER GFP). Mito-
chondria were labeled by using Mitotracker Deep red
dye as already described [31]. We noticed that APPswe
expressing cells exhibit a significant increased co-
localization of the ER and mitochondria as compared
to control cells (evidenced by an increase of mito-
chondria volume in contact with the ER versus total
mitochondria volume) (Fig. 4A). Accordingly, we
also revealed increased mitochondria in contact with
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Fig. 3. -secretase and -secretase complex are present and active
in MAMs fraction in mice brains. A) Representative SDS-PAGE
of subcellular fractions isolated from APP23 transgenic mice as in
Fig. 1 showing the expression of -seceretase complex (cleaved
Presenilin 1 N-terminal fragment (PS1-NT); Anterior Pharynx-
Defective 1 (Aph1); and Nicastrin (NCT)) and of -secretase
(BACE-1). B) Cell-free A production from recombinant C100
peptide performed at 37◦C or 4◦C in the presence of subcellular
fractions isolated from APP23 transgenic mice. C100 and Awere
detected using 6E10 antibody. C) In vitro-secretase specific activ-
ity in WT and APP23 mice brain fractions. The graph represents
-secretase specific activity obtained by subtracting residual activ-
ity in the presence of -secretase inhibitor from total -secretase
activity and is expressed in fluorescent units (FU)/hour (h)/mg of
proteins of each fraction. Data are presented as Mean ± S.E.M.
obtained from 3 independent experiments. Differences are statisti-
cally non-significant using ANOVA one-way and Newman-Keuls
Multicomparison post-test.
the ER by electron microscopy in cells overexpress-
ing APPswe as compared to controls (Fig. 4B).
These data demonstrate that APP muta-
tion/overexpression and most likely its proteolytic
products lead to increased ER-mitochondria contact
sites.
The increased ER-mitochondria contacts in SH-
SY5Y neuroblastoma APPswe cell model may depend
on mitochondrial or ER shape and volume. Supple-
mentary experiments are necessary to fully study this
issue.
Overexpression of AβPP familial mutations
increases neutral lipids accumulation
MAM have the proprieties of an intracellular lipid
raft [21]. This micro-domain is also the site of phos-
pholipid synthesis and transport between the ER and
mitochondria [36]. We explored the potential lipid
dysfunction in relation with APP and its catabo-
lites presence in the MAM and increased ER and
mitochondria contacts. In particular, lipid droplets are
found in close proximity with the ER and mitochon-
dria [37, 38].
We used LipidTox GreenTM dye to stain and quan-
tify neutral lipid accumulation (major components
of lipid droplets). Whereas the lipidTox stain in
control CHO cells reveal few positive droplets, the
CHO cells expressing APPLDN contained numerous
lipidTox positive droplets (∼2-fold over control
cells) (Fig. 5A, B). Similar results were also observed
in SH-SY5Y neuroblastoma cells expressing APPswe
as compared to its respective control cells (Supple-
mentary Figure 6A, B). Importantly, the increase
in lipid droplets in CHO cells expressing APPLDN
was reversed by inhibition of - or -secretases.
As expected, both inhibitors block A production
(Supplementary Figure 6C). However, while the
inhibitor of -secretase strongly reduces C99 frag-
ment production, inhibitor of -secretase enhances
the accumulation of this fragment (Supplementary
Figure 6C). Based on these results, we may postulate
that lipid droplets accumulation in our study models
is likely linked to the production of A peptides
instead of CTFs.
We further demonstrate the specificity of our data
regarding the reduction of neutral lipid accumulation
obtained with - and -secretase inhibitors observed
in CHO cells expressing the London APP mutant.
First, we analyzed neutral lipid accumulation in
na¨ive SH-SY5Y cells upon the application of exoge-
nous oligomeric A (Fig. 5C, 5D). We could indeed
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Fig. 4. Increased ER-mitochondria contact sites in SH-SY5Y cells expressing APPswe. A) Quantitative analyses of the colocalization of
ER and mitochondria in SH-SY5Y live cells expressing pcDNA3.1 [Control (n = 4) or APPswe (n = 7)]. ER is visualized by transfecting ER
GFP (green). Mitochondria are stained with Mitotracker Deep red dye (red). Merge images show overlay of green and red signals. Insets
(magnified overlay) showing ER and mitochondria colocalization depicted in yellow. The graph represents the quantification of ER and
mitochondria colocalization presented as percentage of total mitochondrial volume (% mean ± S.E.M.). **p value < 0.01 using Student’s
t test. Scale bars represent 5m. B) Representative electron microscopy micrographs of control and APPswe expressing cells. Red arrows
show mitochondria in contacts with ER. High magnificence of ER-mitochondria contacts is shown for APPswe cells. Data are presented as
% of mitochondria in contacts with ER. Quantification was obtained from a total number of mitochondria in control (n = 195) and in APPswe
expressing cells (n = 166). Scale bars represent 2m.
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Fig. 5. Increased neutral lipid droplets accumulation in CHO cells expressing APPLDN. A) Representative images showing neutral lipids
staining in CHO control cells or expressing APPLDN. Cells were treated with vehicle or with - or -secretase inhibitors for 20 h. Scale bars
represent 25m. B) The graph shows the quantification of lipid droplets (mean ± S.E.M. number of puncta/cell). The number of analyzed
cells is indicated for each condition and was obtained from at least three independent experiments. *p value < 0.05, and **p value < 0.01 using
ANOVA one way and Tukey post-test. C) Representative images showing neutral lipids staining in SH-SY5Y cells non treated or treated
with 5M oligomeric A (oA) preparation for 20 h. Scale bars represent 10m. D) The graph shows the quantification of lipid droplets
(mean ± S.E.M. number of puncta/cell). The number of analyzed cells is indicated for each condition and was obtained from two independent
experiments. *p value < 0.05, using Student t-test. E) Representative SDS-PAGE of oligomeric A (3M and 6M) preparation.
show that the treatment with exogenous oligomeric
A leads to increased neutral lipid accumulation
(Fig. 5C, D). However, since our A preparation
contains both monomeric and oligomeric forms of
A (Fig. 5E), we cannot conclude whether neutral
lipids accumulation is linked to either monomeric or
oligomeric A (Fig. 5E). Second, we analyzed neural
lipid accumulation in mouse embryonic fibroblasts
(MEF) isolated from wild type (expressing endoge-
nous APP) (WT MEF), or invalidated for APP and
its family member APLP2 (referred to as APP-TKO
MEF) [39]. We established that knock out of APP
did not affect neutral lipid accumulation (Supplemen-
tary Figure 6D). Importantly, we did not notice an
effect of both - and -secretase inhibitors neither in
WT MEF, nor in APP-TKO MEF cells (Supplemen-
tary Figure 6D).
All over, these data demonstrates that neutral lipid
accumulation is likely linked to APP overexpression
and processing and to A production.
Protein interactome of AβPP and its catabolites
in MAMs
Since we showed that APP is present and is pro-
cessed in MAMs likely contributing to increased
ER-mitochondria contact sites, we hypothesized
that APP and its catabolites may thus interact
with proteins localized in this micro-domain. We
used immunoprecipitation combined to proteomic
approach to reveal APP and its catabolites protein
interactome in MAMs. By using 6E10 antibody, we
expected to immunoprecipitate MAMs proteins inter-
acting directly or indirectly with APP holoprotein,
D. Del Prete et al. / AβPP Localization and Processing in MAMs 1561
C99, and/or A peptides. To exclude false positives
due to adsorption of MAMs proteins with IgG beads,
we incubated MAMs fractions isolated from CHO
cells expressing pcDNA4 (Control) or APPLDN with
IgG beads alone (Supplementary Figure 7). We vali-
dated our experimental procedure by revealing APP
peptides (accession number: P12023) in MAMs frac-
tion isolated from APPLDN CHO cells but not in CHO
control cells, thus providing a positive control of our
experimental protocol (Supplementary Figure 8).
We specifically immunoprecipitated 135 proteins
from CHO APPLDN MAM fraction (obtained in 6E10
immunoprecipitate conditions, but not in samples
incubated with IgG beads alone) (Supplementary
Figure 7). In the analyses, we excluded IgG and ribo-
somal proteins. Among immunoprecipitated proteins
from CHO APPLDN MAMs fraction, 39 were also
identified in CHO control MAMs fraction. The com-
mon proteins identified in both samples may reflect
MAMs proteins interacting with full length APP
rather than those interacting with C99 and A pep-
tides. Indeed, the amount of APP catabolites was
clearly lower in control as compared to APPLDN
MAMs fraction (Supplementary Figure 1).
We analyzed the subcellular localization and bio-
logical functions of the 96 unique proteins obtained in
CHO APPLDN MAMs fraction by using gene onthol-
ogy (GO) annotation and UniProt (Universal Protein
Resource) database. In this study, we exclude from
the analysis proteins showing nuclear, extracellular
or microtubule localization. We then determined that
38 proteins are resident in mitochondria (44%); 23
proteins have ER localization (27%), 12 proteins are
mainly cytosolic (14%), 7 proteins are found in lyso-
somes, Golgi apparatus, and endosomes (8%), and 6
proteins are associated with the plasma membrane
(7%) (Supplementary Figure 7). It is important to
note that mitochondria and ER comprise 71% of
the total immunoprecipitated proteins. However, pro-
teins associated with other organelles should not be
discounted as contaminants since the plasma mem-
brane, Golgi apparatus, and lysosomes all have tight
association with the ER or mitochondria and may exe-
cute fundamental cellular functions in these contact
microdomains [40, 41].
We then analyzed the types of function of the
proteins identified. Of most interest, the identi-
fied molecular functions (Supplementary Figure 7)
are mostly attributable to MAMs functions [41,
42]. We focused on the four most significant bio-
logical processes: 1) mitochondrial function and
transport (n = 23) (Supplementary Figure 7 and
Table 1); 2) protein synthesis, maturation, folding,
processing, and degradation (n = 18) (Supplemen-
tary Figure 7 and Table 2); 3) vesicle formation
and trafficking (n = 12) (Supplementary Figure 7
and Table 3); and 4) fatty-acid metabolism (n = 10)
(Supplementary Figure 7 and Table 4). The remain-
ing pathways correspond to proteins implicated in
mitochondria and ER structure (n = 3), apoptosis
(n = 2), cellular signaling (n = 7), and other metabolic
pathways (n = 4) (Supplementary Figure 7 and
Table 1).
Protein interactome related to mitochondrial
function
The identified mitochondrial proteins (n = 23) are
implicated in mitochondrial respiratory chain com-
plexes (n = 9), mitochondrial transport (n = 6), and
mitochondrial metabolism (n = 8) (Supplementary
Figure 7 and Table 1). Interestingly, 6 out of 10
isolated mitochondrial respiratory chain proteins are
components or chaperone proteins of the mitochon-
drial complex I. We also identified Cytochrome
b-c1 complex subunit1 (component of the mito-
chondrial respiratory chain complex III), and two
components of the mitochondrial ATP synthase
complex (Supplementary Figure 7 and Table 1).
The protein interactome of APP and its catabo-
lites related to mitochondrial function include also
proteins implicated in mitochondrial metabolism
(e.g., Acyl-CoA, and coenzyme Q biosynthesis)
(Table 1). In accordance with already reported data,
our approach allowed us to identify proteins impli-
cated in mitochondrial transport (e.g., TIM, and
TOM complexes) [8, 43, 44] (Supplementary Fig-
ure 7 and Table 1). This result could be considered
as a positive control validating our experimental
procedure.
Protein interactome related to protein synthesis,
maturation, folding, processing, and degradation
We identified different proteins implicated in ER
protein maturation (e.g., glycosylation and signal
peptidase complex), protein folding (e.g., inhibi-
tion of protein aggregation of misfolded proteins,
protein quality control), and protein processing
and degradation (e.g., peptidases, proteases) (Sup-
plementary Figure 7 and Table 2). The protein
interactome includes also chaperone proteins inhibit-
ing the aggregation of misfolded proteins (e.g.,
the protein disulfide-isomerase A4, the protein
1562 D. Del Prete et al. / AβPP Localization and Processing in MAMs
Table 1
Classification of protein interactome of the APP and its catabolites related to mitochondrial function
UniProt ID Name(a) Peptides (95%)(b) Function
Mitochondrial respiratory chain complexes
Q9CZ13 Cytochrome b-c1 complex subunit 1,
mitochondrial GN = Uqcrc1
3 Component of complex III or cytochrome b-c1
complex
Q8BGH2(∗) Sorting and assembly machinery component
50 homolog GN = Samm50
2 Maintenance of the structure of mitochondrial
cristae and the proper assembly of the MRC
complexes
Q91VD9 NADH-ubiquinone oxidoreductase 75 kDa
subunit, mitochondrial GN = Ndufs1
1 Core subunit of the mitochondrial Complex I
Q91WD5 NADH dehydrogenase [ubiquinone]
iron-sulfur protein 2, mitochondrial
GN = Ndufs2
1 Core subunit of the mitochondrial Complex I
Q91YT0 NADH dehydrogenase [ubiquinone]
flavoprotein 1, mitochondrial GN = Ndufv1
1 Core subunit of the mitochondrial Complex I
Q9CQN1 Heat shock protein 75 kDa, mitochondrial
GN = Trap1
1 Chaperone protein involved in maintaining
mitochondrial function and polarization,
likely through stabilization of mitochondrial
complex I
Q9CWX2 Complex I intermediate-associated protein 30,
mitochondrial GN = Ndufaf1
1 Chaperone protein involved in the assembly of
the mitochondrial complex I
P97450 ATP synthase-coupling factor 6, mitochondrial
GN = Atp5j
1 Mitochondrial F1F0 ATP synthase or
Complex V
Q9CQQ7 ATP synthase subunit b, mitochondrial
GN = Atp5f1
1 Mitochondrial F1F0 ATP synthase or
Complex V
Mitochondrial transport
Q9Z0V7 Mitochondrial import inner membrane
translocase subunit Tim17-B
GN = Timm17b
1 Essential component of the TIM23 complex
Q8BGH2(∗) Sorting and assembly machinery component
50 homolog GN = Samm50
2 Assembly of TOM40 into the TOM complex
Q9CPQ3 Mitochondrial import receptor subunit TOM22
homolog GN = Tomm22
1 Central receptor component of the translocase
of the TOM complex
Q9QZD8 Mitochondrial dicarboxylate carrier
GN = Slc25a10
1 Translocation of malonate, malate and
succinate in exchange for phosphate, sulfate,
sulfite or thiosulfate
Q9Z2Z6 Mitochondrial carnitine/acylcarnitine carrier
protein OS = Mus musculus GN = Slc25a20
1 Transport of acylcarnitines of different length
across the mitochondrial inner membrane
Q9CQX2 Cytochrome b5 type B GN = Cyb5b 1 Electron carrier for several membrane bound
oxygenases
Mitochondrial metabolism
Q9JHI5 Isovaleryl-CoA dehydrogenase, mitochondrial
GN = Ivd
1 Synthesis of
(S)-3-hydroxy-3-methylglutaryl-CoA from
3-isovaleryl-CoA
Q9WUM5 Succinyl-CoA ligase [ADP/GDP-forming]
subunit alpha, mitochondrial GN = Suclg1
1 ATP- or GTP-dependent ligation of succinate
and CoA to form succinyl-CoA
Q9R112 Sulfide:quinone oxidoreductase, mitochondrial
GN = Sqrdl
1 Oxidation of hydrogen sulfide with the help of
a quinone, such as ubiquinone
Q9D2G2 Dihydrolipoyllysine-residue
succinyltransferase component of
2-oxoglutarate dehydrogenase complex,
mitochondrial GN = Dlst
1 Conversion of 2-oxoglutarate to succinyl-CoA
and CO2
Q60936 Chaperone activity of bc1 complex-like,
mitochondrial GN = Adck3
1 Biosynthesis of coenzyme Q (ubiquinone)
Q64521 Glycerol-3-phosphate dehydrogenase,
mitochondrial GN = Gpd2
1 Belongs to the FAD-dependent
glycerol-3-phosphate dehydrogenase family
Q99KI0 Aconitate hydratase, mitochondrial GN = Aco2 1 Isomerization of citrate to isocitrate via
cis-aconitate
Q9D051 Pyruvate dehydrogenase E1 component
subunit beta, mitochondrial GN = Pdhb
1 Conversion of pyruvate to acetyl-CoA and
CO2
UniProtID, protein accession number in Swiss-Prot/Trembl. (a)Protein name given by UniProt database. (b)Number of peptides matching the
protein with a confidence limit of 95%. (∗)A protein that have several functions. GN, gene name.
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Table 2
Classification of protein interactome of the APP and its catabolites related to protein synthesis, maturation, folding, processing and
degradation
UniProt ID Name(a) Peptides (95%)(b) Function
Protein synthesis
Q8K0D5 Elongation factor G, mitochondrial GN = Gfm1 2 Mitochondrial GTPase that catalyzes the
GTP-dependent ribosomal translocation
step during translation elongation.
Q8R2Y8 Peptidyl-tRNA hydrolase 2, mitochondrial
GN = Ptrh2
2 The natural substrate for this enzyme may be
peptidyl-tRNAs which drop off the
ribosome during protein synthesis.
Protein maturation or modiﬁcation
Q9DBG6 Dolichyl-diphosphooligosaccharide–protein
glycosyltransferase subunit 2 GN = Rpn2
1 Involved in the pathway of protein
glycosylation
P46978 Dolichyl-diphosphooligosaccharide–protein
glycosyltransferase subunit STT3A
GN = Stt3a
1 Involved in the pathway of protein
glycosylation
Q9R0P6 Signal peptidase complex catalytic subunit
SEC11A GN = Sec11a
1 Component of the microsomal signal
peptidase complex.
Q9CXY9 GPI-anchor transamidase GN = Pigk 1 Involved in the pathway
glycosylphosphatidylinositol-anchor
biosynthesis
Protein folding
P08003 Protein disulfide-isomerase A4 GN = Pdia4 2 Chaperone that inhibits aggregation of
misfolded proteins.
Q922R8 Protein disulfide-isomerase A6 GN = Pdia6 2 Chaperone that inhibits aggregation of
misfolded proteins.
Q9D1M7 Peptidyl-prolyl cis-trans isomerase FKBP11
GN = Fkbp11
2 PPIases accelerate the folding of proteins
during protein synthesis.
Q9Z2G6 Protein sel-1 homolog 1 GN = Sel1l 2 May play a role in Notch signaling. May be
involved in the ER quality control
P24369 Peptidyl-prolyl cis-trans isomerase B GN = Ppib 1 PPIases accelerate the folding of proteins
Q99KV1 DnaJ homolog subfamily B member 11
GN = Dnajb11
1 Co-chaperone for HSPA5. Binds directly to
both unfolded proteins that are substrates
for ERAD
Protein processing and degradation
Q8K411 Presequence protease, mitochondrial
GN = Pitrm1
1 ATP-independent protease that degrades
mitochondrial transit peptides after their
cleavage
Q6I6G8 E3 ubiquitin-protein ligase HECW2
GN = Hecw2
1 Involved in the pathway of protein
ubiquitination,
O70481 E3 ubiquitin-protein ligase UBR1 GN = Ubr1 1 E3 ubiquitin-protein ligase which is a
component of the N-end rule pathway
O88696 Putative ATP-dependent Clp protease proteolytic
subunit, mitochondrial GN = Clpp
1 Protease component of the Clp complex that
cleaves peptides and various proteins in an
ATP-dependent process
Q9QXV0 ProSAAS GN = Pcsk1n 1 Serine-type endopeptidase inhibitor activity
Q9CYN2 Signal peptidase complex subunit 2 GN = Spcs2 1 Component of the microsomal signal
peptidase complex
UniProtID, protein accession number in Swiss-Prot/Trembl. (a)Protein name given by UniProt database. (b)Number of unique peptides
matching the protein with a confidence limit of 95%. GN, gene name.
disulfide-isomerase A6, and the peptidyl-prolyl cis-
isomerase FKBP11), or implicated in the ER
quality control (e.g., the protein sel-1 homolog
1, and the DnaJ homolog subfamily B mem-
ber 11). Interestingly, we also identified proteins
implicated in mitochondrial protein translation, and
the mitochondrial presequence protease involved in
the degradation of mitochondrial transit peptides
(Supplementary Figure 7 and Table 2).
Protein interactome related to vesicle formation
and trafﬁcking
In addition to the mitochondria, the ER is associ-
ated with different subcellular domains that execute
divers function such as vesicular traffic [40]. As a
matter of fact, we identified a class of APP protein
interactome (n = 12) including proteins implicated
in vesicle formation and trafficking (Supplementary
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Table 3
Classification of protein interactome of the APP and its catabolites related to vesicle formation and trafficking
UniProt ID Name(a) Peptides (95%)(b) Function
Q3V009 Transmembrane emp24 domain-containing
protein 1 GN = Tmed1
1 Potential role in vesicular protein trafficking,
mainly in the early secretory pathway
Q9R0Q3 Transmembrane emp24 domain-containing
protein 2 GN = Tmed2
2 Involved in vesicular protein trafficking
(early secretory pathway and post-Golgi
membranes)
Q9D1D4 Transmembrane emp24 domain-containing
protein 10 GN = Tmed10
1 Involved in vesicular protein trafficking
O08917 Flotillin-1 GN = Flot1 1 May act as a scaffolding protein within
caveolar membranes, functionally
participating in formation of caveolae or
caveolae-like vesicles
O55100 Synaptogyrin-1 GN = Syngr1 1 Involved in the regulation of short-term and
long-term synaptic plasticity
P35293 Ras-related protein Rab-18 GN = Rab18 1 Plays a role in apical endocytosis/recycling
P61027 Ras-related protein Rab-10 GN = Rab10 2 Regulator of intracellular membrane
trafficking, may play a role in ER
dynamics and morphology
Q9D1G1 Ras-related protein Rab-1B GN = Rab1b 1 Regulates vesicular transport between the
ER and Golgi compartments. Plays a role
in the initial events of the autophagic
vacuole development
Q61548 Clathrin coat assembly protein AP180
GN = Snap91
1 Components of the adaptor complexes which
link clathrin to receptors in coated vesicles
Q9CQW2 ADP-ribosylation factor-like protein 8B
GN = Arl8b
1 May play a role in lysosomes motility
Q9EQH3 Vacuolar protein sorting-associated protein
35 GN = Vps35
1 Component of the retromer cargo-selective
complex (CSC).
Q9JIG8 PRA1 family protein 2 GN = Praf2 1 May be involved in ER/Golgi transport and
vesicular traffic
UniProtID, protein accession number in Swiss-Prot/Trembl. (a)Protein name given by UniProt database. (b)Number of unique peptides
matching the protein with a confidence limit of 95%. GN, gene name.
Figure 7 and Table 3). These include Ras-related fam-
ily proteins (Rab-10, Rab18, and Rab1b) implicated
in ER-Golgi transport and vesicular traffic, and Praf2
(PRAF1 family protein 2) known to interacts with
numerous Rab GTPases thus assisting in the packag-
ing of Rab proteins into vesicles for the transport to
target compartments [45, 46]. We also revealed other
proteins implicated in vesicular transport namely the
transmembrane emp24 domain containing proteins
(Tmed2, Tmed10, and Tmed1) and Arl8b (an Arf-like
GTPase being a critical regulator of cargo delivery to
lysosomes). We also revealed in the protein interac-
tome Flotillin 1, known to be a scaffolding protein
within caveolar membranes and to interact with lipid
rafts [47, 48].
Protein interactome related to fatty-acid
metabolism
We classified a fourth cellular pathway including
proteins (n = 10) implicated in fatty-acid metabolism
(Supplementary Figure 7 and Table 4). This includes
proteins implicated in fatty-acid elongation or
modification (Hsd17b12, Acot1, Far1), fatty-acid
beta-oxidation (Acaa2, Hadhb, and Acad9), sterol
and cholesterol biosynthesis (Nsdh1, Cyp51a1, Lss),
and sphingolipid metabolism (Sptlc1). Based on GO
annotation, these proteins are mostly localized in the
ER (Hsd17b12, Nsdhl, Sptlc1, Cyp51a1, and Lss),
or in the mitochondria (Acot1, Acaa2, Far1, and
Hadhb,and Acad9). Nsdhl may be also localized in
lipid droplets (Table 4).
All over, these analyses identify potential new
APP and its catabolites interactors in MAMs. How-
ever, a dedicated study is necessary to confirm
specific direct or indirect interactions of APP or
its catabolites with these proteins and their role in
MAMs alteration in AD.
DISCUSSION
We used both biochemical and imaging approaches
to demonstrate the presence of APP and its catabo-
lites in MAMs in in vitro and in in vivo AD-like
models. It is well established that APP is synthe-
D. Del Prete et al. / AβPP Localization and Processing in MAMs 1565
Table 4
Classification of protein intercatome of the APP and its catabolites related to fatty-acid metabolism
UniProt ID Name(a) Peptides (95%)(b) Function
O70503 Estradiol 17-beta-dehydrogenase 12
GN = Hsd17b12
2 Catalyzes the second of the four reactions of
the long-chain fatty acids elongation cycle
Q9R1J0 Sterol-4-alpha-carboxylate
3-dehydrogenase, decarboxylating
GN = Nsdhl
1 Involved in the sequential removal of two
C-4 methyl groups in post-squalene
cholesterol biosynthesis
O35704 Serine palmitoyltransferase 1 GN = Sptlc1 1 Involved in the pathway sphingolipid
metabolism
O55137 Acyl-coenzyme A thioesterase 1 GN = Acot1 1 Catalyze the hydrolysis of acyl-CoAs to the
free fatty acid and coenzyme A (CoASH)
Q8BWT1 3-ketoacyl-CoA thiolase, mitochondrial
GN = Acaa2
1 Involved in the pathway fatty acid beta
oxidation
Q8K0C4 Lanosterol 14-alpha demethylase
GN = Cyp51a1
1 Catalyzes C14-demethylation of lanosterol
Q8JZN5 Acyl-CoA dehydrogenase family member 9,
mitochondrial GN = Acad9
2 Mitochondrial complex I assembly (By
similarity)
Q922J9 Fatty acyl-CoA reductase 1 GN = Far1 1 Catalyzes the reduction of saturated fatty
acyl-CoA with chain length C16 or C18 to
fatty alcohols
Q99JY0 Trifunctional enzyme subunit beta,
mitochondrial GN = Hadhb
1 Involved in the pathway fatty acid
beta-oxidation
Q8BLN5 Lanosterol synthase GN = Lss 1 Catalyzes the cyclization of (S)-2,3
oxidosqualene to lanosterol
UniProtID, protein accession number in Swiss-Prot/Trembl. (a)Protein name given by UniProt database. (b)Number of unique peptides
matching the protein with a confidence limit of 95%. GN, gene name.
sized in the ER [49]. Recent studies reported that
APP is also associated with mitochondria in AD
affected neurons [50, 51]. This was further sup-
ported by the presence of APP catabolites (i.e., A,
C99, and AICD) in the mitochondria [9, 52–55]. We
report in this study APP localization, and process-
ing in MAMs. These results were obtained in two
distinct cellular systems (SH-SY5Y and CHO cells)
expressing wild type APP or harboring two differ-
ent familial mutations (APPswe and APPLDN) thus
demonstrating that the observed presence and pro-
cessing of WT or mutated APP in MAMs is not
linked to a specific cell type and not to a specific
familial APP mutation. This may also reveal that
the subcellular localization and proteolytic process-
ing of APP in MAMs was not linked to AD familial
cases but may also be observed in sporadic cases of
AD. These data also suggest that even if trafficking
of APP may vary according to the mutation, transit
through MAMs compartment where APP undergo
cleavage is a common denominator independent of
the nature of the APP species.
We also revealed the presence and activity of -
, -, and -secretases in the MAMs. -secretase
was shown to exert its activity in the plasma mem-
brane but also in other intracellular compartments
such as the trans-Golgi network, lysososmes, pure
mitochondria fraction, and MAMs [16, 20, 56].
However, it is important to emphasize that even if
-secretase complex has been found in mitochondria
[16], the putative generation of intra-mitochondrial
A and C99 remains puzzling, given the C-terminus-
out orientation of APP in the outer mitochondrial
membrane [9]. A hypothetical model has been pro-
posed stating that Amay be produced at the interface
between the ER and mitochondria and then trans-
ferred to the mitochondria via the TOM import
machinery [9, 44]. Another gap to envision the pro-
duction of A in mitochondria was the demonstration
of the presence of active -secretase (BACE-1) in
mitochondria or in MAMs. Importantly, we report
herein and for the first time the presence of BACE-1
in crude mitochondria and MAMs fractions. Cur-
rent knowledge on APP and BACE-1 trafficking
indicates that plasma membrane and endosomes are
likely the major sites of BACE-1-mediated cleavage
of APP [57, 58]. Mature BACE-1 localizes largely
within plasma membrane cholesterol-rich lipid rafts
[57, 58], and replacing the BACE-1 transmembrane
domain with a glycosylphosphatidylinositol anchor
extensively targets BACE-1 to lipid rafts and sub-
stantially increases A production [59]. In addition,
various types of lipids stimulate BACE-1 activ-
ity [60]. Interestingly, a recent study revealed that
MAMs behave as a detergent-resistant lipid raft-like
domain, consistent with the presence and activity of
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- and -secretase in rafts [21, 61–63]. In accordance
with the presence of -CTF fragment in MAMs, we
also could measure an in vitro -secretase activity
in this compartment in mice brains (Supplementary
Figure 5D). Other experiments are still needed to
further characterize expression and subcellular dis-
tribution and trafficking of -secretase in vitro and
in vivo. We must take into account that both - and
-secretases harbor optimal activities in acidic com-
partments and that the pH of the ER is almost neutral
(pH 7.2), and that of mitochondria matrix is markedly
alkaline (pH 8) [64]. Thus, it remains not clear how
these enzymes may function in the ER, mitochon-
dria, and MAMs compartments in intact cells. One
may postulate that APP, or at least its C-terminal
fragments (C99/C83), and BACE-1 are transported to
the ER-mitochondria contact sites through a mech-
anism implicating retrograde vesicular trafficking.
Indeed, we identified different proteins related to
vesicle formation and trafficking in the protein inter-
actome data of MAMs fraction isolated from CHO
cells expressing APPLDN (Table 3). Dedicated exper-
iments are necessary to confirm this hypothesis and to
further explore the molecular mechanisms underlying
BACE-1 localization and in situ function in MAMs.
We report an increased ER-mitochondria con-
tact sites in SH-SY5Y cells overexpressing APPswe.
Accordingly, an increased ER-mitochondria connec-
tivity was detected in human fibroblasts isolated from
individuals with familial AD mutations as well as
sporadic AD cases, and in MEFs isolated from mice
simple or double knockout for PS1 or PS2 [21].
Similar results were obtained in neuroblastoma cells
expressing familial AD-linked PS2 mutations [35].
Interestingly, increased ER-mitochondria connectiv-
ity was also reported in a transgenic AD mouse model
expressing mutant tau protein [65], and most recently,
in cells exposed to apolipoprotein E (ApoE4), a
major risk factor for developing sporadic AD [66].
These results and our data may lead to consider
MAMs structural alteration as a common denomi-
nator underlying the pathogenesis of AD associated
to both sporadic and APP/PS-linked familial AD
mutations. In agreement with these data, the pro-
teomic approach revealed potential APP interactors
implicated in the regulation of mitochondrial and
ER structure (Dnajc11 and atlastin 3 respectively)
(Supplementary Table 1) [67–69]. Accordingly, post-
mortem analysis of human AD brain and those of AD
mouse models showed altered expression levels of
PACS2 and Sigma1R, thus further establishing dereg-
ulated MAMs as a hallmark of AD [70]. Moreover,
it is interesting to note that APP processing relies
on intact ER-mitochondria crosstalk [21]. Thus, cells
deficient of MFN2 show diminished MAM function
in terms of lipid metabolism and reduced -secretase
activity by approximately 50% [21]. In turn, expos-
ing hippocampal neurons or neuroblastoma cells to
A enhances ER-mitochondria contacts [70, 71].
These observations are in favor of a vicious cycle
where APP is processed in MAMs, and its derivative
catabolites enhance ER-mitochondria communica-
tion and function.
We analyzed a second aspect of MAMs func-
tion in AD by combining immunoprecipitation and
proteomic mass spectrometric analysis to identify
molecules that associate with APP and its prote-
olytic products in MAMs. This approach allows the
unbiased and extensive exploration of all possible
direct or indirect protein interactors. Nevertheless,
we may consider some limitations of the approach
used here namely the difficulty to identify interac-
tors of lower expression. This approach failed also to
reveal components of -secretase and/or -secretase
in MAM proteome analyses. This may be explained
by the limitation of immunoprecipitation approach
and/or to instable interaction of APP and its cleav-
ing enzymes. Although, the strength of our data is
supported by the identification of APP interactors
described in previous studies using distinct exper-
imental approaches (i.e., TIM/TOM complex) [8,
43, 44]. Furthermore, we also revealed new pro-
tein partners belonging to cellular pathways known
to participate to AD pathogenesis. Interestingly, six
out of nine of APP and its catabolites interactome
related to mitochondrial respiratory chain complexes
are components or chaperone of complex I. Previ-
ous studies have revealed that A may cause both
a selective defect in complex I activity associated
with an increase of intracellular reactive oxygen
species [72, 73]. We also unraveled an interaction
of APP and or its catabolites with the mito-
chondrial ATP synthase (complex V). Interestingly
this enzyme shows reduced activity in AD affected
brains [74].
We revealed the interaction of APP and its
catabolites with several proteins implicated in protein
synthesis, maturation, folding, processing, and degra-
dation. Several studies have suggested that altered
maturation, processing, and degradation of APP
holoprotein may drive the availability of APP for
A generation [75–78]. It was also suggested that dif-
ferent PPIases regulate A production, or the toxicity
associated with A [79]. Concerning mitochondria,
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we showed that APP and its catabolites may directly
or indirectly interact with mitochondrial presequence
protease (PreP, GN: pitrm), a pitrilysin metallopepti-
dase 1 implicated in the degradation of mitochondrial
transit peptides after their cleavage. PreP has been
shown to degrade various A peptides thus clearing
mitochondrial (A) [80, 81]. Accordingly, increased
neuronal PreP activity attenuates neuroinflammation
and improves mitochondrial and synaptic function in
AD mice model [82, 83].
Finally, we delineate in this study the potential
interaction of APP and its catabolites with different
proteins related to fatty-acid metabolism. Accord-
ingly, we show increased neutral lipids accumulation
in both neuroblastoma and CHO cells expressing
APPswe or APPLDN. Neutral lipids accumulation
was reported in different AD study models includ-
ing PS-mutant MEFs, PS double knockout MEFs,
fibroblasts from familial AD patients [21], and more
recently fibroblasts exposed to ApoE4 conditioned
media [66]. We also revealed that neutral lipids accu-
mulation in our study models is likely linked to A
peptides rather to C99 fragment. A more dedicated
study is necessary to investigate the molecular mech-
anisms underlying lipid droplets accumulation in AD.
In particular, lipid droplets are found in close prox-
imity with the ER and mitochondria [37, 38], and
the functions of these interactions are still largely
unknown. It is, however, noticeable that proteolytic
cleavage of APP is tightly regulated by several lipids
such as cholesterol and sphingolipids. In turn, A
as well as other APP processing products play an
essential role in regulating lipid homeostasis [84].
Moreover, in vitro studies have shown that fatty acids
may affect A secretion [85].
In summary, our data extends the previous stud-
ies suggesting MAMs as an important contributor to
AD pathogenesis. Maintenance and tight regulation
of MAM structure and function could be envisioned
as potential therapeutic strategies for AD.
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